GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

SHR-1918

SHR-1918

Company
Beijing Suncadia Pharmaceuticals Co., Ltd
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
3 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

3 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for SHR-1918 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07230730

    A Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia

    Not yet reported Beijing Suncadia Pharmaceuticals Co., Ltd 900 participants Est. completion 2027-10 1 site Stand-alone
    Other conditions: Hyperlipidemia
    View official trial listing →
  • Recruiting NCT NCT07349615

    A Study of SHR-1918 In Participants With Hypertriglyceridemia

    Not yet reported Beijing Suncadia Pharmaceuticals Co., Ltd 360 participants Est. completion 2027-11 1 site Stand-alone
    Other conditions: Hypertriglyceridemia
    View official trial listing →
  • Recruiting NCT NCT07404553

    A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors

    Not yet reported, Not yet reported Beijing Suncadia Pharmaceuticals Co., Ltd 126 participants Est. completion 2028-08 1 site Stand-alone
    Other conditions: Hypercholesterolemia
    View official trial listing →
  • Status unknown NCT NCT05432544

    Safety and Tolerability of SHR-1918 in Healthy Subjects

    Not yet reported Beijing Suncadia Pharmaceuticals Co., Ltd 72 participants Est. completion 2023-12-12 1 site Stand-alone
    Other conditions: Hyperlipemia
    View official trial listing →
  • Completed NCT NCT06009393

    Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

    Not yet reported Beijing Suncadia Pharmaceuticals Co., Ltd 26 participants Est. completion 2024-08-23 1 site Stand-alone
    Other conditions: Homozygous Familial Hypercholesterolemia
    View official trial listing →
  • Completed NCT NCT06109831

    Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic

    Not yet reported Beijing Suncadia Pharmaceuticals Co., Ltd 335 participants Est. completion 2025-07-04 1 site Stand-alone
    Other conditions: Hyperlipidemic
    View official trial listing →
  • Completed NCT NCT06471218

    Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia

    Not yet reported Beijing Suncadia Pharmaceuticals Co., Ltd 44 participants Est. completion 2025-05-16 1 site Stand-alone
    Other conditions: Hyperlipidemia
    View official trial listing →
  • Completed NCT NCT06723652

    A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

    Not yet reported Beijing Suncadia Pharmaceuticals Co., Ltd 55 participants Est. completion 2025-11-18 1 site Stand-alone
    Other conditions: Homozygous Familial Hypercholesterolemia
    View official trial listing →
  • Not yet recruiting NCT NCT07133815

    Evaluate the Long-term Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

    Not yet reported Beijing Suncadia Pharmaceuticals Co., Ltd 55 participants Est. completion 2027-12 1 site Stand-alone
    Other conditions: Homozygous Familial Hypercholesterolemia
    View official trial listing →
  • Active, not recruiting NCT NCT07308392

    Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis

    Not yet reported Fujian Shengdi Pharmaceutical Co., Ltd. 119 participants Est. completion 2027-06 1 site Stand-alone
    Other conditions: Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.